Cargando…

Cyclosporine in Cholinergic Itch

Cholinergic itch is part of symptom complex that also includes cholinergic erythema and cholinergic urticaria. It mostly occurs during the winters among young adults. It is characterized by onset of severe itching or burning sensation all over body, mostly, on exposure to sunlight, warm atmosphere a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehgal, Sumit, Arora, Vanshika, Gupta, Lalit, Khare, Ashok Kumar, Vyas, Kapil, Mittal, Asit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917483/
https://www.ncbi.nlm.nih.gov/pubmed/35287416
http://dx.doi.org/10.4103/idoj.idoj_584_21
_version_ 1784668555969560576
author Sehgal, Sumit
Arora, Vanshika
Gupta, Lalit
Khare, Ashok Kumar
Vyas, Kapil
Mittal, Asit
author_facet Sehgal, Sumit
Arora, Vanshika
Gupta, Lalit
Khare, Ashok Kumar
Vyas, Kapil
Mittal, Asit
author_sort Sehgal, Sumit
collection PubMed
description Cholinergic itch is part of symptom complex that also includes cholinergic erythema and cholinergic urticaria. It mostly occurs during the winters among young adults. It is characterized by onset of severe itching or burning sensation all over body, mostly, on exposure to sunlight, warm atmosphere and in some cases after hot and spicy food intake. In most of the cases, it is poorly responsive to antihistamine therapy. MATERIALS AND METHODS: This was a prospective, open labeled, clinical study done in patients of cholinergic itch, refractory to both sedating and non sedating anti-histamine drugs, who attended dermatology clinic of our tertiary care center from November, 2020 to February, 2021. Oral cyclosporine was given as treatment. Numerical rating scale (NRS) was used to record the treatment response. RESULTS: Twenty patients with cholinergic itch meeting inclusion criteria were included in the study. Mean age of disease onset was 19.5 years. Average duration of each episode was 4.4-8 minutes. More than one site was involved in all patients with trunk being the commonest (100%). There was significant reduction in the number of episodes and cholinergic itch severity (mean NRS=7.8 to 0.3 at the end of second week after initiating cyclosporine therapy). P value of the study was <0.0001. STATISTICS: Mean and standard deviation were used as measure of central tendency. Paired t test was applied to analyze the data obtained. CONCLUSION: Oral cyclosporine effectively controlled cholinergic itch in all included patients. Drug was well tolerated by the patients.
format Online
Article
Text
id pubmed-8917483
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-89174832022-03-13 Cyclosporine in Cholinergic Itch Sehgal, Sumit Arora, Vanshika Gupta, Lalit Khare, Ashok Kumar Vyas, Kapil Mittal, Asit Indian Dermatol Online J Brief Report Cholinergic itch is part of symptom complex that also includes cholinergic erythema and cholinergic urticaria. It mostly occurs during the winters among young adults. It is characterized by onset of severe itching or burning sensation all over body, mostly, on exposure to sunlight, warm atmosphere and in some cases after hot and spicy food intake. In most of the cases, it is poorly responsive to antihistamine therapy. MATERIALS AND METHODS: This was a prospective, open labeled, clinical study done in patients of cholinergic itch, refractory to both sedating and non sedating anti-histamine drugs, who attended dermatology clinic of our tertiary care center from November, 2020 to February, 2021. Oral cyclosporine was given as treatment. Numerical rating scale (NRS) was used to record the treatment response. RESULTS: Twenty patients with cholinergic itch meeting inclusion criteria were included in the study. Mean age of disease onset was 19.5 years. Average duration of each episode was 4.4-8 minutes. More than one site was involved in all patients with trunk being the commonest (100%). There was significant reduction in the number of episodes and cholinergic itch severity (mean NRS=7.8 to 0.3 at the end of second week after initiating cyclosporine therapy). P value of the study was <0.0001. STATISTICS: Mean and standard deviation were used as measure of central tendency. Paired t test was applied to analyze the data obtained. CONCLUSION: Oral cyclosporine effectively controlled cholinergic itch in all included patients. Drug was well tolerated by the patients. Wolters Kluwer - Medknow 2022-03-03 /pmc/articles/PMC8917483/ /pubmed/35287416 http://dx.doi.org/10.4103/idoj.idoj_584_21 Text en Copyright: © 2022 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Brief Report
Sehgal, Sumit
Arora, Vanshika
Gupta, Lalit
Khare, Ashok Kumar
Vyas, Kapil
Mittal, Asit
Cyclosporine in Cholinergic Itch
title Cyclosporine in Cholinergic Itch
title_full Cyclosporine in Cholinergic Itch
title_fullStr Cyclosporine in Cholinergic Itch
title_full_unstemmed Cyclosporine in Cholinergic Itch
title_short Cyclosporine in Cholinergic Itch
title_sort cyclosporine in cholinergic itch
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917483/
https://www.ncbi.nlm.nih.gov/pubmed/35287416
http://dx.doi.org/10.4103/idoj.idoj_584_21
work_keys_str_mv AT sehgalsumit cyclosporineincholinergicitch
AT aroravanshika cyclosporineincholinergicitch
AT guptalalit cyclosporineincholinergicitch
AT khareashokkumar cyclosporineincholinergicitch
AT vyaskapil cyclosporineincholinergicitch
AT mittalasit cyclosporineincholinergicitch